Aim to develop targeted therapies designed to activate a specific isoform of AMPK to improve glucose and lipid homeostas while mitigating safety concerns.
OLUMIANT is the first JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support.
Will supply 388,000 doses of etesevimab to complement doses of bamlanivimab previously purchased, with approximately 200,000 doses expected to ship 3Q21.